STOCK TITAN

United Therapeutics (UTHR) EVP exercises options and sells 8,300 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics executive vice president and general counsel Paul A. Mahon exercised stock options and sold the resulting shares in a planned transaction. On May 7, 2026, he exercised options for 8,300 shares of common stock at a strike price of $146.03 per share and carried out open‑market sales totaling 8,300 shares.

The sales were executed in multiple trades at prices including about $597.54, $596.19, $588.51 and several weighted‑average prices in the mid‑$580s, according to footnotes. The filing states these transactions were made under a pre‑arranged Rule 10b5‑1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider MAHON PAUL A
Role EVP & GENERAL COUNSEL
Sold 8,300 shs ($4.87M)
Type Security Shares Price Value
Exercise Stock Option 8,300 $0.00 --
Exercise Common Stock 8,300 $146.03 $1.21M
Sale Common Stock 80 $582.8575 $47K
Sale Common Stock 1,475 $584.0698 $862K
Sale Common Stock 994 $585.1779 $582K
Sale Common Stock 1,689 $586.1724 $990K
Sale Common Stock 2,970 $587.6086 $1.75M
Sale Common Stock 820 $588.5084 $483K
Sale Common Stock 70 $596.19 $42K
Sale Common Stock 202 $597.54 $121K
Holdings After Transaction: Stock Option — 300 shares (Direct, null); Common Stock — 53,472 shares (Direct, null)
Footnotes (1)
  1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. This transaction was executed in multiple trades at prices ranging from $582.42 to $583.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $583.72 to $584.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $584.83 to $585.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $585.86 to $586.695. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $587.185 to $588.105. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $588.195 to $588.7025. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 8,300 shares Open-market sales of common stock on May 7, 2026
Option shares exercised 8,300 shares Stock options converted into common stock on May 7, 2026
Option strike price $146.03 per share Exercise price for stock options converted into common shares
Sale block price $597.54 per share One reported open-market sale of 202 shares
Sale block price $596.19 per share One reported open-market sale of 70 shares
Largest sale block 2,970 shares Single largest trade of common stock on May 7, 2026
Remaining options 300 options Stock options remaining after the 8,300-share exercise
Rule 10b5-1 plan financial
"exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
stock options financial
"This is an exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MAHON PAUL A

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & GENERAL COUNSEL
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/2026M(1)8,300A$146.0353,472D
Common Stock05/07/2026S(1)80D$582.8575(2)53,392D
Common Stock05/07/2026S(1)1,475D$584.0698(3)51,917D
Common Stock05/07/2026S(1)994D$585.1779(4)50,923D
Common Stock05/07/2026S(1)1,689D$586.1724(5)49,234D
Common Stock05/07/2026S(1)2,970D$587.6086(6)46,264D
Common Stock05/07/2026S(1)820D$588.5084(7)45,444D
Common Stock05/07/2026S(1)70D$596.1945,374D
Common Stock05/07/2026S(1)202D$597.5445,172D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$146.0305/07/2026M(1)8,30003/15/202003/15/2027Common Stock8,300$0.00300D
Explanation of Responses:
1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
2. This transaction was executed in multiple trades at prices ranging from $582.42 to $583.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $583.72 to $584.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $584.83 to $585.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $585.86 to $586.695. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $587.185 to $588.105. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $588.195 to $588.7025. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did UTHR executive Paul Mahon report?

Paul A. Mahon reported an exercise-and-sell transaction involving stock options. He exercised options for 8,300 shares of United Therapeutics common stock and sold all 8,300 resulting shares in multiple open-market trades on May 7, 2026 under a pre-arranged plan.

How many United Therapeutics (UTHR) shares did Paul Mahon sell?

Paul Mahon sold 8,300 shares of United Therapeutics common stock. The Form 4 shows eight separate open-market sale transactions on May 7, 2026, with individual trade blocks ranging from 70 shares to 2,970 shares, all tied to the exercised stock options.

At what prices were Paul Mahon’s UTHR share sales executed?

The reported sales prices ranged from about $582 to just under $598 per share. Specific blocks include 202 shares at $597.54, 70 shares at $596.19, and several weighted-average prices around $585–$588, as detailed in the transaction table and related footnotes.

Did Paul Mahon’s UTHR transactions involve stock options?

Yes. Mahon exercised stock options covering 8,300 shares of United Therapeutics common stock at a strike price of $146.03 per share. A corresponding derivative entry shows these options converting into common shares, which were then sold in the same-day open-market transactions.

Were Paul Mahon’s UTHR share sales under a Rule 10b5-1 plan?

Yes. A footnote states the option exercise and resulting share sales were made under a pre-arranged Rule 10b5-1 trading plan. That plan was entered into by the reporting person on August 11, 2025, indicating the trades were scheduled in advance rather than timed opportunistically.

Does Paul Mahon still hold United Therapeutics stock options after this filing?

Yes, the derivative transaction table shows 300 stock options remaining after the exercise of 8,300 options. The exercised options originally had an exercise date of March 15, 2020 and an expiration date of March 15, 2027, with a conversion rate of one option to one common share.